학술논문

Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts
Document Type
article
Source
Acta Neuropathologica. 144(1)
Subject
Biomedical and Clinical Sciences
Neurosciences
Clinical Research
Alzheimer's Disease
Acquired Cognitive Impairment
Aging
Brain Disorders
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurodegenerative
Alzheimer's Disease Related Dementias (ADRD)
Dementia
Behavioral and Social Science
2.1 Biological and endogenous factors
Aetiology
Neurological
Aged
80 and over
Alzheimer Disease
Amyloid
Autopsy
DNA-Binding Proteins
Frontotemporal Dementia
Humans
Male
Nervous System Diseases
Plaque
Amyloid
ADRD
Tau
NFT
Nondemented
Oldest-old
Epidemiology
APOE
ROS-MAP
Vantaa 85+
HAAS
CFAS
CC75C
The 90+study
ACT
VITA
Nun study
Biobank for aging studies
Mayo clinic study of aging
The 90 + study
Vantaa 85 + 
Clinical Sciences
Neurology & Neurosurgery
Language
Abstract
Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and Alzheimer's disease neuropathologic change (ADNC) are each associated with substantial cognitive impairment in aging populations. However, the prevalence of LATE-NC across the full range of ADNC remains uncertain. To address this knowledge gap, neuropathologic, genetic, and clinical data were compiled from 13 high-quality community- and population-based longitudinal studies. Participants were recruited from United States (8 cohorts, including one focusing on Japanese-American men), United Kingdom (2 cohorts), Brazil, Austria, and Finland. The total number of participants included was 6196, and the average age of death was 88.1 years. Not all data were available on each individual and there were differences between the cohorts in study designs and the amount of missing data. Among those with known cognitive status before death (n = 5665), 43.0% were cognitively normal, 14.9% had MCI, and 42.4% had dementia-broadly consistent with epidemiologic data in this age group. Approximately 99% of participants (n = 6125) had available CERAD neuritic amyloid plaque score data. In this subsample, 39.4% had autopsy-confirmed LATE-NC of any stage. Among brains with "frequent" neuritic amyloid plaques, 54.9% had comorbid LATE-NC, whereas in brains with no detected neuritic amyloid plaques, 27.0% had LATE-NC. Data on LATE-NC stages were available for 3803 participants, of which 25% had LATE-NC stage > 1 (associated with cognitive impairment). In the subset of individuals with Thal Aβ phase = 0 (lacking detectable Aβ plaques), the brains with LATE-NC had relatively more severe primary age-related tauopathy (PART). A total of 3267 participants had available clinical data relevant to frontotemporal dementia (FTD), and none were given the clinical diagnosis of definite FTD nor the pathological diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). In the 10 cohorts with detailed neurocognitive assessments proximal to death, cognition tended to be worse with LATE-NC across the full spectrum of ADNC severity. This study provided a credible estimate of the current prevalence of LATE-NC in advanced age. LATE-NC was seen in almost 40% of participants and often, but not always, coexisted with Alzheimer's disease neuropathology.